Echinomycin (NSC 526417) in Advanced Ovarian Cancer: A Phase II Trial of the Gynecologic Oncology Group
Abstract
Twenty-two patients with recurrent carcinoma of the ovary progressive after initial chemotherapy (21 with cisplatin-based treatment) were entered on a phase II trial utilizing Echinomycin at a dosage of 1,500 micrograms/m2 every 4 weeks. There were two complete responders and no partial responders (9% response, 95% confidence intervals for complete and partial responses of 1-29%). Major toxicity was modest and consisted mainly of nausea and vomiting. Echinomycin displays minimal activity as salvage therapy in women with advanced ovarian cancer at this dose and schedule.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Clinical studies have provided considerable safety data for echinomycin.
“Clinical studies have provided considerable safety data for echinomycin10-12, 14-18, 41-45”
From Liposomal Formulation of HIF-1α Inhibitor Echinomycin Eliminates Established Metastases of Triple-negative Breast Cancer (2020) · cites this paper as [42]
Cited by
Sorted by citations
Bui, B. P., Nguyen, P. L., Lee, K., & Cho, J. (2022) · Cancers · doi:10.3390/cancers14246054 · Cited by 164 · see citing works
Dawson, S. J., Malkinson, J. P., Paumier, D., & Searcey, M. (2006) · Natural Product Reports · doi:10.1039/b516347c · Cited by 99 · see citing works
Energetics of echinomycin binding to DNA
Leng, F. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg826 · Cited by 96 · see citing works
“Actinomycin has found a lasting place in the clinic for the treatment of various uncommon and fast-growing cancers, but echinomycin was eventually withdrawn from clinical trial on account of its toxicity without marked therapeutic benefit ( 10 ).”
BackgroundQuinomycin A targets Notch signaling pathway in pancreatic cancer stem cells
Ponnurangam, S., Dandawate, P. R., Dhar, A., Tawfik, O. W., Parab, R., Mishra, P. D., Ranadive, P., Sharma, R. K., Mahajan, G., Umar, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6560 · Cited by 64 · see citing works
“Moreover, National Cancer Institute sponsored phase II clinical trials has demonstrated anti-tumor efficacy of Quinomycin using various treatment schedules for various cancer types [9–19].”
BackgroundTherapeutic Targeting of Hypoxia-Inducible Factors in Cancer
Din, S. M. U., Streit, S., Huynh, B. T., Hana, C. K., Abraham, A. N. J., & Hussein, A. M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042060 · Cited by 57 · see citing works
Bailey, C. M., Liu, Y., Peng, G., Zhang, H., He, M., Sun, D., Zheng, P., Liu, Y., & Wang, Y. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102278 · Cited by 44 · see citing works
Sayers, E. W., & Waring, M. J. (1993) · Biochemistry · doi:10.1021/bi00086a014 · Cited by 36 · see citing works
Natural product inhibitors of ovarian neoplasia
da Silva, J. S., Moura, M. D., de Oliveira, R. A. G., et al. (2003) · Phytomedicine · doi:10.1078/094471103321659988 · Cited by 29 · see citing works
The Gynecologic Oncology Group experience in ovarian cancer
McGuire, W. P., Brady, M. F., & Ozols, R. F. (1999) · Annals of Oncology · doi:10.1016/s0923-7534(20)31481-2 · Cited by 28 · see citing works
Echinomycin and Related Quinoxaline Antibiotics
Waring, M. J. (1993) · doi:10.1007/978-1-349-12356-8_7 · Cited by 19 · see citing works
Satange, R., Chang, C.-C., Li, L., Lin, S., Neidle, S., & Hou, M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad156 · Cited by 17 · see citing works
PARK, J. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2004.01.005 · Cited by 15 · see citing works
Chen, C., Chen, X., Ren, B., Guo, H., Abdel-Mageed, W. M., Liu, X., Song, F., & Zhang, L. (2021) · Journal of Industrial Microbiology & Biotechnology · doi:10.1093/jimb/kuab079 · Cited by 14 · see citing works
“…agent, echinomycin has been evaluated by phase II clinical trial from the 1990s (Brown et al., 1991; Chang et al.1998; Gradishar et al., 1995; Hakes et al., 1990; Marshall et al., 1993; Muss et al., 1990, 1993; Schilsky et al., 1991; Shevrin et al., 1994; Taylor et al., 1990; Wadler et al., 1994).”
MethodPark, Y. S., Shin, W., Kim, C.-S., Ahn, C. M., Qi, X.-F., & Kim, S. (2018) · Molecular & Cellular Toxicology · doi:10.1007/s13273-018-0002-8 · Cited by 14 · see citing works
Echinomycin: A Journey of Challenges
Lafi, Z., Alshaer, W., Hatmal, M. M., Zihlif, M., Asha, N., Abdelnabi, H., & Awidi, A. (2023) · Jordan Journal of Pharmaceutical Sciences · doi:10.35516/jjps.v16i3.918 · Cited by 11 · see citing works
“Echinomycin advanced to phase I and II clinical trials for various cancer diseases, including endometrial carcinoma, ovarian cancer, soft tissue sarcoma, and others (Table 1) (6, 9, 47).”
Xu, L., Ishikawa, H., Zhou, Y., Kobayashi, T., & Shozu, M. (2022) · F&S Science · doi:10.1016/j.xfss.2022.01.005 · Cited by 6 · see citing works
Repurposing payloads: next generation of antibody–drug conjugates
Shatzer, K., & Müller, F. L. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.04.001 · Cited by 7 · see citing works
The bisintercalator family of nonribosomal peptides: structural diversity and biosynthetic mechanism
Shi, X. (2025) · Natural Product Reports · doi:10.1039/d5np00003c · Cited by 2 · see citing works
- Authors
- Muss, H. B., Blessing, J. A., Baker, V. V., Barnhill, D. R., & Adelson, M. D.
- Affiliations
- Atrium Health Wake Forest Baptist (US)
- ORCID
- Muss, Hyman B.
- Venue
- American Journal of Clinical Oncology
- Published
- 1990-08
- Volume
- 13
- Issue
- 4
- Pages
- 299-301
- ISSN
- 0277-3732 (ISSN-L)
- OpenAlex
- W1997166008
- Cited by
- 18
- References
- 0
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 1 · 2018: 1 · 2015: 1
- FWCI
- 0.90
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5u10ca012484-17)
- National Cancer Institute (CA12484, CA23501, CA 19502)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- echinomycin, advanced ovarian cancer, recurrent ovarian cancer, salvage chemotherapy, cisplatin-refractory disease, complete response, topoisomerase I inhibitor
- MeSH terms
- Adult, Aged, Carcinoma, Drug Evaluation, Echinomycin, Female, Humans, Infusions, Intravenous, Middle Aged, Neoplasm Recurrence, Local, Ovarian Neoplasms, Quinoxalines, Remission Induction, Multicenter Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
